Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Nephrology | Urology
Disease Category: Nocturia
Location: United States, IN
A randomized, double, placebo-controlled, parallel group study to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia.
SER120 will be administered intra-nasally as a single spray in either the left or right nostril each night before bedtime. The placebo will also be administered this same way.
CW ID: 178191
Date Last Changed:
May 2, 2014
Debbie Johnson, CCRC, Director of ResearchFirst Urology, PSC101 Hospital Blvd.Jeffersonville, IN 47130Phone: (812) 206-8161Fax: (812) 288-2612
Research Center Information: First Urology, PSC
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.